4.6 Article

Integrin αMβ2 is differently expressed by subsets of human osteoclast precursors and mediates adhesion of classical monocytes to bone

Journal

EXPERIMENTAL CELL RESEARCH
Volume 350, Issue 1, Pages 161-168

Publisher

ELSEVIER INC
DOI: 10.1016/j.yexcr.2016.11.018

Keywords

Integrin alpha M beta 2; Cell adhesion to bone; Monocytes; Osteoclast precursors

Funding

  1. Marie Curie Initial Training Network (Euroclast)
  2. Marie Curie Initial Training Network (FP7-People-2013-ITN) [607447]

Ask authors/readers for more resources

Bone-degrading osteoclasts are formed through fusion of their monocytic precursors. In the population of human peripheral blood monocytes, three distinct subsets have been identified: classical, intermediate and non-classical monocytes. We have previously shown that when the monocyte subsets are cultured on bone, significantly more osteoclasts are formed from classical monocytes than from intermediate or non-classical monocytes. Considering that this difference does not exist when monocyte subsets are cultured on plastic, we hypothesized that classical monocytes adhere better to the bone surface compared to intermediate and non-classical monocytes. To investigate this, the different monocyte subsets were isolated from human peripheral blood and cultured on slices of human bone in the presence of the cytokine M-CSF. We found that classical monocytes adhere better to bone due to a higher expression of the integrin alpha M beta 2 and that their ability to attach to bone is significantly decreased when the integrin is blocked. This suggests that integrin alpha M beta 2 mediates attachment of osteoclast precursors to bone and thereby enables the formation of osteoclasts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cell Biology

Diabetes Medication Metformin Inhibits Osteoclast Formation and Activity in In Vitro Models for Periodontitis

Lucy Y. Tao, Katarzyna B. Lagosz-Cwik, Jolanda M. A. Hogervorst, Ton Schoenmaker, Aleksander M. Grabiec, Tim Forouzanfar, Fridus A. van der Weijden, Teun J. de Vries

Summary: Research suggests that metformin has beneficial effects on the periodontal status of periodontitis patients by inhibiting osteoclast formation and activity, potentially benefiting the bone as a whole.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Review Biotechnology & Applied Microbiology

Gene Therapy for Fibrodysplasia Ossificans Progressiva: Feasibility and Obstacles

Elisabeth M. W. Eekhoff, Ruben D. de Ruiter, Bernard J. Smilde, Ton Schoenmaker, Teun J. de Vries, Coen Netelenbos, Edward C. Hsiao, Christiaan Scott, Nobuhiko Haga, Zvi Grunwald, Carmen L. De Cunto, Maja di Rocco, Patricia L. R. Delai, Robert J. Diecidue, Vrisha Madhuri, Tae-Joon Cho, Rolf Morhart, Clive S. Friedman, Michael Zasloff, Gerard Pals, Jae-Hyuck Shim, Guangping Gao, Frederick Kaplan, Robert J. Pignolo, Dimitra Micha

Summary: Fibrodysplasia ossificans progressiva (FOP) is a rare and devastating genetic disease where soft connective tissue turns into heterotopic bone. Although the genetic defect is known, effective treatments have been hindered by the complexity of the disease. Gene therapy shows promise as a therapeutic option for FOP, but the role of the immune system and the primary causative cell remain unknown.

HUMAN GENE THERAPY (2022)

Article Rheumatology

Mutation in the CCAL1 locus accounts for bidirectional process of human subchondral bone turnover and cartilage mineralization

Alejandro Rodriguez Ruiz, Marcella van Hoolwerff, Sara Sprangers, Eka Suchiman, Ton Schoenmaker, Petra Dibbets-Schneider, Johan L. Bloem, Rob G. H. H. Nelissen, Christian Freund, Christine Mummery, Vincent Everts, Teun J. de Vries, Yolande F. M. Ramos, Ingrid Meulenbelt

Summary: The study demonstrates the mechanism by which the readthrough mutation in TNFRSF11B leads to a bidirectional phenotype of subchondral bone turnover and cartilage mineralization in chondrocalcinosis patients. OPG-XL expression results in excessive fibrosis in cartilage and high mineralization in bone, accompanied by altered gene expression of MGP and DIO2.

RHEUMATOLOGY (2022)

Review Medicine, General & Internal

Limitations of Jaw Movement in Fibrodysplasia Ossificans Progressiva: A Review

Ton Schoenmaker, Amine Dahou Bouchankouk, Semih ozkan, Marjolijn Gilijamse, Elinor Bouvy-Berends, Coen Netelenbos, Frank Lobbezoo, Elisabeth Marelise W. Eekhoff, Teun J. de Vries

Summary: Fibrodysplasia ossificans progressiva (FOP) is a rare genetic disorder characterized by abnormal bone formation in the muscles, tendons, and ligaments. This study aimed to evaluate the age of onset and location of bone formation and the resulting functional restrictions in the jaw of FOP patients. The results showed that bone formation is more common in females and trauma-induced bone formation occurs at a younger age than spontaneous bone formation. Additionally, the location of bone formation in the maxillofacial region affects the degree of restriction in jaw movement.

FRONTIERS IN MEDICINE (2022)

Article Dentistry, Oral Surgery & Medicine

Intra-pulpal connective tissue formation and the advanced carious lesion: Is chondrogenesis and heterotopic ossification a response to pulpal inflammation?

Sune Demant, Ton Schoenmaker, Sophie M. G. van Erck, Sally Dabelsteen, Teun J. de Vries, Lars Bjorndal

Summary: The formation of dense connective tissue within the dental pulp and its association with pulpal inflammation in teeth with advanced carious lesions were investigated in this study. In addition, the study investigated whether inflammation affects the expression of markers related to chondrogenesis/osteogenesis in pulp cells in vitro.

INTERNATIONAL ENDODONTIC JOURNAL (2022)

Article Biochemistry & Molecular Biology

TGF-Beta Induces Activin A Production in Dermal Fibroblasts Derived from Patients with Fibrodysplasia Ossificans Progressiva

Ruben D. D. de Ruiter, Lisanne E. E. Wisse, Ton Schoenmaker, Maqsood Yaqub, Gonzalo Sanchez-Duffhues, E. Marelise W. Eekhoff, Dimitra Micha

Summary: FOP is an ultra-rare disease caused by genetic defects in the ACVR1 gene. We found that FOP patients have elevated Activin A production in their fibroblasts, and TGF beta 1 is a specific stimulant of Activin A in FOP. This study is the first to identify TGF beta 1 as a triggering factor of Activin A production in FOP, suggesting it as a possible therapeutic target.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Biochemistry & Molecular Biology

A Systematic Review of the Evidence of Hematopoietic Stem Cell Differentiation to Fibroblasts

Bernard J. Smilde, Esmee Botman, Teun J. de Vries, Ralph de Vries, Dimitra Micha, Ton Schoenmaker, Jeroen J. W. M. Janssen, Elisabeth M. W. Eekhoff

Summary: Fibroblasts play a crucial role in maintaining the extracellular matrix of connective tissues. Recent studies have found donor-derived fibroblasts in bone marrow transplant recipients, though some findings were not replicated. This systematic review provides an overview of hematopoietic stem cells differentiating into fibroblasts in various tissues, revealing evidence of fibroblasts derived from hematopoietic stem cells in almost all organs.

BIOMEDICINES (2022)

Article Biochemistry & Molecular Biology

Transcriptomic Differences Underlying the Activin-A Induced Large Osteoclast Formation in Both Healthy Control and Fibrodysplasia Ossificans Progressiva Osteoclasts

Ton Schoenmaker, Joy Zwaak, Bruno G. Loos, Richard Volckmann, Jan Koster, E. Marelise W. Eekhoff, Teun J. de Vries

Summary: Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disease characterized by progressive heterotopic ossification that leads to immobility and premature death. It is caused by a mutation in the ACVR1 gene, resulting in altered response to Activin-A. Activin-A induces changes in osteoclastogenesis at the gene expression level, regardless of the presence of the mutated ACVR1 receptor. RNA sequencing analysis revealed differentially expressed genes and enriched pathways associated with osteoclast differentiation, cell fusion, and inflammation. These findings suggest that Activin-A plays a significant role in gene expression during osteoclast formation in FOP.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Article Biochemistry & Molecular Biology

The Effect of Sclerostin and Monoclonal Sclerostin Antibody Romosozumab on Osteogenesis and Osteoclastogenesis Mediated by Periodontal Ligament Fibroblasts

Karina E. Pigeaud, Melanie L. Rietveld, Aster F. Witvliet, Jolanda M. A. Hogervorst, Chen Zhang, Tim Forouzanfar, Nathalie Bravenboer, Ton Schoenmaker, Teun J. de Vries

Summary: Sclerostin is an inhibitor of bone formation produced by osteocytes, and it has been reported to be expressed in periodontal ligament fibroblasts as well. This study aimed to explore the role of sclerostin and its inhibitor romosozumab in osteogenesis and osteoclastogenesis. The results showed that sclerostin did not affect the osteogenic capacity of periodontal ligament fibroblasts, while romosozumab slightly reduced osteoclast formation in co-cultures with peripheral blood mononuclear cells at high concentrations. Further analysis revealed significant differences in the expression of SOST and its receptors between osteocytes and periodontal ligament cells.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Review Endocrinology & Metabolism

The Differential Effect of Metformin on Osteocytes, Osteoblasts, and Osteoclasts

Teun J. de Vries, Antonella S. Kleemann, Jianfeng Jin, Ton Schoenmaker

Summary: Metformin has differential effects on bone cells, promoting bone formation while inhibiting bone resorption. It lowers the expression of negative regulators of bone formation in osteocytes and shifts the osteoblasts' regulation of bone resorption towards decrease RANKL expression and increase OPG expression. Metformin also activates bone formation parameters in osteoblast lineage cells and inhibits osteoclast formation and activity. These effects are likely mediated by the activation of phosphorylated AMP kinase (AMPK). Overall, metformin shows promising potential as a drug in the field of bone research.

CURRENT OSTEOPOROSIS REPORTS (2023)

No Data Available